Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Arvinas and Pfizer Collaborate on Out-Licensing Vepdegestrant to Enhance Cancer Treatment.

Sep 17, 2025•9 months ago

Contract Type

partnership

New HavenBiotechnologyHealth CareTherapeuticsresearch

Description

Arvinas, Inc. has updated its collaboration with Pfizer on the co-development of vepdegestrant and announced efforts to out-license its commercialization rights. The companies are actively seeking a third-party partner to maximize the drug's commercial potential for advanced breast cancer treatment.

Company Information

Company

Arvinas

Location

5 Science Park

New Haven, Kentucky, United States

About

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer; and vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Arvinas's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months